Ranbaxy to Appeal U.S. District Court Decision Upholding Pfizer Atorvastatin Patents.
PR Newswire Europe, December, 2005
PRINCETON, New Jersey, December 17 /PRNewswire/ -- Ranbaxy Laboratories Limited announced today that the U.S. District Court of Delaware ruled against Ranbaxy in its case for non-infringement and invalidation of two Pfizer patents on atorvastatin. Atorvastatin is a cholesterol-lowering drug, marketed by Pfizer as Lipitor(R), and is the largest-selling drug in the world.
Judge Joseph J. Farnan held that Ranbaxy's atorvastatin infringes Pfizer's U.S. Patent No. 4,681,893, and at the same time upheld the validity of another, Pfizer U.S. Patent No. 5,273,995 which Ranbaxy had claimed was invalid. The ruling followed a hearing in the U.S. District Court of Delaware, which took place in December 2005. Ranbaxy plans to begin the appeals process immediately....
- 5 Rules for Immediate Annuities
- Death in the Family: 12 Things to Do Now
- Dumbest Things You Do With Your Money
- 6 Online Networking Mistakes to Avoid
- 401(k) Mistakes to Avoid
- 5 Economic Scenarios to Keep You Up at Night
- The Real ‘Best Places to Retire’
- Best Credit Cards for You
- 12 Tough Questions to Ask Your Parents
- The Real ‘Best Colleges’
- Home Buyer Tax Credit: How to Cash In
- Why You Shouldn't Bash Cash
- 8 Phony 'Bargains' and Better Alternatives
- Danger: 3 Debit Card Scams to Avoid
- 6 Myths About Gas Mileage
- 29 Fees We Hate Most
- Quick and Easy Ways to Boost Returns
- Best Stocks to Buy Now
- Lower Your Taxes: 10 Moves to Make Now
- New Jobs: 8 Lessons from Real-Life Career Switchers
- The New Job Market: Who Wins and Who Loses?
- Health Care Reform's Public Option: Everything You Need to Know
- Volunteer Work When Unemployed: Should You Work for Free?
- Whose Recovery Is This?
- Long-Term-Care Insurance: 4 Biggest Risks to Avoid
Most Recent Business Articles
- Multiple criteria evaluation and optimization of transportation systems
- Multi-criteria analysis procedure for sustainable mobility evaluation in urban areas
- A two-leveled multi-objective symbiotic evolutionary algorithm for the hub and spoke location problem
- Multi-criteria analysis for evaluating the impacts of intelligent speed adaptation
- The development of Taiwan arterial traffic-adaptive signal control system and its field test: a Taiwan experience
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FAS 109: a primer for non-accountants - Financial Accounting Standards Board's "Statement 109: Accounting for Income Taxes"
- LIFO vs. FIFO: a return to the basics
- Too Young to Rent a Car? - 25-years-old the minimum age for car renting - Brief Article
- Design a commission plan that drives sales - Sales Commissions
Presented by American Express